Ian Bolland is joined by Martin Gouldstone and Ray Valencia from Sensyne Health to explain more about the use of synthetic control arms, clinical trial transformation, speeding up the process and its SENSIGHT platform – which works within the NHS.
Professor Saad Shakir, director of the Drug Safety Research Unit looks at observational research in the UK and why it's one of the nation's core strengths.
Ivor Campbell managing director of Stirlingshire-based Snedden Campbell explores the use of blood tests to diagnose cancer and questions whether the NHS’ latest approach is the right one.
Reece Armstrong speaks to Cathal Friel, chairman and co-founder of Open Orphan, about the company's involvement in setting up the first human challenge study model for Covid-19 and the importance of studying the virus during the pandemic.
Paul O’Donohoe, Scientific Lead, eCOA and Mobile Health at Medidata explores how using digital platforms and remote solutions can give the broadest picture of patient response.
Igor Kruglyak, senior advisor at the global IT service provider Avenga and Michael DePalma, founder and president of digital specialists Pensare, LLC, examine the use of natural language processing (NLP) for investigator recruitment acceleration.
Anders Mortin, co-founder of consulting company TriTiCon looks at the three key steps for start-ups and growing companies wanting to maximise the value of trial data.
We speak to Dr Sarah Halford, head of Medical Sciences, Cancer Research UK Centre for Drug Development about its latest virtual clinical trial and its Covid-19 efforts.
Fernando Geijo and Xavier Ruiz, manager of QA for R&D and QRD auditor, respectively, at Azbil Telstar discuss the importance of adopting good practices in clinical research.
Sukirti Kalra clinical project manager and Colin Newboul, head of Global Regulatory Affairs & Quality at Wasdell Group examine how clinical trials are adapting with the ongoing Covid-19 pandemic.
